The designation will help the company accelerate the process of bringing the opioid addiction risk test through regulatory review and clearance.

CNN reports that researchers have tied a new variant to opioid addiction risk.

The guidelines are the first to attempt to specify which drugs are appropriate to test for routinely, guideline authors say.

Prescient Medicine says its genetic test can identify people who may be at a higher risk of developing an opioid addiction, Fast Company reports.

The university is marshaling the expertise across all its schools in studying myriad factors that might contribute to opioid response, addiction, and abuse.

The company joins others in a still-controversial setting, hoping to market its test to help guide the prescription of narcotic pain medications.

Proove Biosciences responds to its visit by federal investigators and concerns surrounding its tests and business approaches.

Federal investigators have searched the offices of Proove Biosciences, Stat News reports.

The Philadelphia Inquirer writes that a genetic test to gauge opioid abuse risk might not work.

The agency is seeking grant applications for projects investigating the molecular genetics underlying drug addiction and related co-morbidities.


A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.

A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more